GlassScriptPhysician profile
Elizabeth A Sekul
NPI 1215048269
$8,255.42
in general payments reported to CMS, 2019-2025
46 companies · $76.30 in 2025
The $76.30 reported for 2025 was less than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,477 · 2020: $891 · 2021: $1,157 · 2022: $1,520 · 2023: $1,817 · 2024: $1,317 · 2025: $76.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,210.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,265.33 | 2019-2025 | Briviact, Fintepla, Rystiggo |
| Sunovion Pharmaceuticals INC. | $803.76 | 2019-2022 | |
| Greenwich Biosciences, INC. | $575.27 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $529.38 | 2019-2022 | |
| Neurelis, INC. | $509.07 | 2021-2024 | Valtoco |
| Jazz Pharmaceuticals INC. | $494.26 | 2022-2024 | |
| Sk Life Science, INC. | $377.58 | 2020-2024 | |
| Genentech USA, INC. | $349.71 | 2019-2024 | Evrysdi |
| Alexion Pharmaceuticals, INC. | $322.09 | 2019-2024 | Ultomiris, Soliris |
| Sarepta Therapeutics, INC. | $278.74 | 2020-2023 | Exondys 51 |
| Eisai INC. | $261.13 | 2019-2023 | |
| Abbvie INC. | $252.60 | 2023-2025 | Botox |
| Ns Pharma, INC. | $249.57 | 2021-2024 | Viltepso |
| Biogen, INC. | $220.85 | 2021-2024 | Spinraza |
| Grifols USA, LLC | $218.07 | 2019-2024 | Gamunex-C |
Show all 45 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Sekul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.